1. Introduction {#sec1}
===============

Axonal spinal arthritis (axSpA) is a clinically common chronic progressive inflammatory disease caused by cellular stresses \[[@B1], [@B2]\]. Ankylosing spondylitis (AS) is a representative disease of axSpA, accompanied by structural damage to the sacroiliac joints (such as narrowing of joint space, erosion, and subchondral bone sclerosis) observed by X-ray examinations \[[@B3], [@B4]\]. In severe cases, spinal rigidity, deformity, and dysfunction have even occurred and seriously affected the quality of life of patients \[[@B5]\]. AS is more common in young men, and it is one of the major causes of the loss of labor force in China\'s young and middle-aged people \[[@B6]\]. Recent investigations suggest that disease pathogenesis is ascribed to a complex interplay of genetic, environmental, endocrine disorders, and autoimmune function \[[@B7], [@B8]\].

Several studies demonstrated that the persistence of inflammation is an important predisposing factor of subsequent structural articular damage \[[@B9], [@B10]\]. Until now, there is no available method for early diagnosis of AS. And the effective therapy for AS stays largely undefined. Experts in related fields believe that the main therapeutic goal of AS is to prevent the progressive structural damage by controlling symptoms and inflammation to maintain the body function of the patient, thereby maximizing social participation and improving long-term quality of life \[[@B11]\]. According to the guidelines for the treatment of axial spondyloarthritis developed by the American College of Rheumatology in 2016 \[[@B11]\], the optimal management of AS requires a combination of pharmacological and nonpharmacological treatment models. At present, the first-line drugs for treating AS are nonsteroidal anti-inflammatory drugs (NSAIDs) \[[@B12]\], which are often supplemented with antirheumatic drugs, glucocorticoids, biological agents, and traditional Chinese medicine (TCM) \[[@B13], [@B14]\]. Nonpharmacological treatments include physiotherapy, physical exercise, and health education for patients and their families \[[@B13], [@B14]\]. The serious complications of advanced AS include hip fusion, spinal deformity, and a spinal fracture. If necessary, surgeries such as total hip arthroplasty and spine surgery should be performed. AS is a chronic disease requiring long-term medication. The long-term medication will cause serious adverse reactions and economic burden \[[@B15], [@B16]\].

Besides, many meta-analyses have shown an increased risk of cardiovascular events associated with NSAIDs \[[@B17]--[@B19]\]. Therefore, it is still urgently required to look for effective, safe, and cost-effective treatment methods that can treat AS through other mechanisms \[[@B20]\].

In TCM, the plant *Sinomenium acutum* (in China known as Fang-ji or Qing-feng-teng), a Chinese herbal medicine, is widely used to treat rheumatic arthritis and has the advantages of mild toxicity and no addiction \[[@B21]\]. Sinomenine is an alkaloid originally isolated from the root of *Sinomenium acutum*. Its medicinal form is generally hydrochloride \[[@B22]\]. Studies have shown that sinomenine has anti-inflammatory \[[@B23], [@B24]\], immunosuppression \[[@B25]\], cartilage protection \[[@B26], [@B27]\], vascular endothelium protection \[[@B28]\], analgesic \[[@B29]\], and other effects. At present, sinomenine preparation (SP) approved by the State Food and Drug Administration of China includes Zhengqing Fengtongning Conventional Tablet, Zhengqing Fengtongning Sustained Release Tablet, Zhengqing Fengtongning Enteric-Coated Tablet, Zhengqing Fengtongning Capsule, and Zhengqing Fengtongning Injection. Many clinical trials have shown that SP has a good therapeutic effect on AS \[[@B30], [@B31]\]. Therefore, as a modern preparation, SP is expected to become an emerging and special medicine for the treatment of AS and has broad prospects \[[@B32], [@B33]\]. Because the sample size of a single study is too small, the level of evidence for the efficacy and safety of the SP in the treatment of AS is very low. Therefore, it is necessary to conduct a systematic review and meta-analysis to evaluate the efficacy and safety of SP in the treatment of AS, to objectively provide a reference for the rational use of drugs and individual treatment in the clinic.

2. Methods {#sec2}
==========

2.1. Selection Criteria {#sec2.1}
-----------------------

### 2.1.1. Study Design {#sec2.1.1}

Clinical randomized controlled trials (RCTs) of SP for the treatment of AS were included.

### 2.1.2. Participants {#sec2.1.2}

Studies indicated that the diagnostic criteria were nationally recognized New York classification criteria for AS \[[@B3]\]. And participants did not have serious complications. There were no restrictions on participants\' gender, age, race, duration of disease, source of the case, and follow-up time.

### 2.1.3. Interventions {#sec2.1.3}

The experimental group used sinomenine preparation (SP) alone or SP combined with conventional pharmacotherapy (CPT). The type of preparation and the route of administration are not limited. The SP included Zhengqing Fengtongning Conventional Tablet, Zhengqing Fengtongning Sustained Release Tablet, Zhengqing Fengtongning Enteric-Coated Tablet, Zhengqing Fengtongning Capsule, and Zhengqing Fengtongning Injection. The control group used CPT alone. The CPT included NSAIDs, antirheumatic drugs, immunosuppressants, and biological agents. Both the experimental group and the control group were not combined with other traditional Chinese medicine prescriptions, Chinese herbal compound decoctions, external dressings, or fumigation lotions containing sinomenine extract.

### 2.1.4. Outcomes {#sec2.1.4}

Studies using at least one of the following outcomes were included.

*(1) Primary Outcomes*. Recognized standardized scales: bath ankylosing spondylitis disease activity index (BASDAI) \[[@B34]\] and bath ankylosing spondylitis functional index (BASFI) \[[@B35]\].

*(2) Secondary Outcomes*.   ① Clinical symptom measures: morning stiffness time, the Schober test, chest expansion, occipital wall test, finger-to-ground distance, and 15 m walking time  ② Laboratory measures: erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) play an important role in judging the severity of AS \[[@B10], [@B36], [@B37]\]  ③ Total effective rate depending on the degree of improvement of clinical symptoms and laboratory measures  ④ Adverse reactions

### 2.1.5. Exclusion Criteria {#sec2.1.5}

  ① Interventions include other TCM treatments, such as traditional Chinese medicine decoction, other Chinese patent medicine, acupuncture, and rehabilitation therapy  ② After seeking help online or contacting the corresponding author via e-mail, studies whose full text cannot be obtained need to be excluded  ③ Studies that do not provide data for synthesis will be excluded  ④ For studies that repeatedly published by different centers, we only included the one with the most complete results and the highest quality  ⑤ Unfinished protocol, case report, systematic review, and meta-analysis were excluded

2.2. Search Strategy {#sec2.2}
--------------------

The clinical RCTs about SP in the treatment of AS were searched in the relevant database, including PubMed, Embase, Cochrane Library (No. 10 of 2019), China National Knowledge Infrastructure (CNKI), Wan Fang database, and VIP database. The retrieval time was from inception to October 2019. The search terms mainly included Zhengqing Fengtongning, Sinomenine, ankylosing spondylitis, randomized controlled trial, and their synonyms. The search strategies combining medical subject headings (MeSH) and free-text terms were used. Different search strategies were adopted according to the characteristics of each database. The synonyms in every group are connected by "or," and the search terms between the groups are connected by "and." At the same time, the reference lists of existing systematic reviews and meta-analyses were further searched to avoid omissions. The language of the literature was not limited. The development and implementation of the search strategy were completed by a clinician Lin and a methodologist Liu and revised by the library staff. The detailed search strategy of PubMed as an example was shown in [Table 1](#tab1){ref-type="table"}.

2.3. Data Extraction and Quality Evaluation {#sec2.3}
-------------------------------------------

The data extraction contents mainly included sample data, diagnostic criteria, interventions, efficacy criteria, outcomes, and adverse reactions. Finally, according to the Cochrane\'s risk of bias tool including random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias, the methodological qualities of the included studies were assessed with "low" (representing the low risk of bias), "unclear" (for medium or unknown risk of bias), or "high" (for high risk of bias) \[[@B38]\]. Data extraction and quality evaluation were performed by two reviewers (Lin and Liu) independently according to the selection criteria, and disagreements were resolved through discussion with the third reviewer (Zhang).

2.4. Statistical Analysis {#sec2.4}
-------------------------

Data analysis was performed using Review Manager 5.3 software. The risk ratio (RR) or odds ratio (OR) with a 95% confidence interval (CI) was calculated for dichotomous outcomes. The weighted mean difference (WMD) or standardized mean difference (SMD) with 95% CI was calculated for continuous outcomes. *P* \< 0.05 was considered to be statistically significant. The statistical heterogeneity was estimated according to *I*^2^ statistics. If the results had no statistical heterogeneity (*P*≧0.1, *I*^2^ ≦ 50%), a fixed-effect model would be used to combine analysis. When there was statistical heterogeneity (*P* \< 0.1, *I*^2^ \> 50%), the subgroup analysis would be needed if there was obvious clinical or methodological heterogeneity. If no obvious clinical or methodological heterogeneity was found, a random-effect model would be used. For the results of the original study that could not be used for meta-analysis, we would perform a qualitative descriptive analysis. If the number of studies included was sufficient (≧10 articles), a funnel plot would be drawn to analyze for potential publication bias.

3. Results {#sec3}
==========

3.1. Literature Search Result {#sec3.1}
-----------------------------

We identified a total of 282 studies of the potentially relevant literature in the initial retrieval. Firstly, we read the title and abstract to exclude the literature whose content was irrelevant. Secondly, we read the full text to determine whether it would be eventually included. Finally, twelve studies \[[@B39]--[@B50]\] published from 2001 to 2014 were included. The literature screening process and the result were shown in [Figure 1](#fig1){ref-type="fig"}.

3.2. Basic Conditions of the Included Studies {#sec3.2}
---------------------------------------------

Twelve RCTs involving 835 patients were included. According to the interventions, the included studies were divided into two types of treatment comparisons. The first type was SP combined with CPT (SP + CPT) versus CPT in 10 RCTs. The second type was SP alone versus CPT in 2 RCTs. CPT included sulfasalazine, meloxicam, methotrexate, thalidomide, inflammatory pain tablet, vitamins, and ranitidine. The duration of the treatment was one month to 18 months. See [Table 2](#tab2){ref-type="table"} for details.

3.3. Quality Assessment of Included Studies {#sec3.3}
-------------------------------------------

All studies used randomization, but only three studies \[[@B44], [@B49], [@B50]\] detailed that the specific method of random sequence generation was to use a random number table. We considered them to be low risk. None of the studies mentioned allocation concealment. Almost all the studies did not mention the blinding of participants and outcome assessment. However, one study \[[@B41]\] was a prospective-open-controlled trial, which indicated that blinding was not used. We considered that both the risk of performance bias and the risk of detection bias were high. None of the studies had attrition bias due to incomplete outcome data. In terms of selective reporting, three studies \[[@B42], [@B45], [@B50]\] did not report all of the preset outcomes in the results section, such as radiographs of the sacroiliac joint, lumbar spine, and chest. In one study \[[@B41]\], although the results were tested multiple times, only one of them was reported. Therefore, we considered them \[[@B41], [@B42], [@B45], [@B50]\] to be a high risk of reporting bias. All studies did not have sufficient evidence to support the existence of other biases. Overall, the quality of 10 studies is low or remains unclear due to the high proportion of the unclear risk of biases in most studies. The results of the quality assessment are summarized in [Figure 2](#fig2){ref-type="fig"}.

3.4. Data Analyses of SP + CPT versus CPT {#sec3.4}
-----------------------------------------

The first type of intervention comparisons was SP + CPT versus CPT, including ten studies \[[@B39]--[@B48]\]. The results of data analyses are as follows.

### 3.4.1. Clinical Symptom Measures {#sec3.4.1}

*(1) BASDAI*. Two of these studies \[[@B44], [@B46]\] used the internationally recognized BASDAI scoring standard. Because of the significant heterogeneity (*P* \< 0.00001, *I*^2^ = 95%), a random-effect model was used. [Figure 3](#fig3){ref-type="fig"} shows that oral SP + CPT may be more beneficial to reduce the BASDAI than CPT in treating AS (WMD = −1.84, 95% CI \[−3.31, −0.37\], *P*=0.01). Only one study \[[@B47]\] using injectable SP + CPT reported BASDAI, so no meta-analysis was performed. The experimental group used injectable SP (intra-articular injection, 35 ml, once a week) based on the treatment of the control group. Jie et al. \[[@B47]\] thought that there was no statistically significant difference between injectable SP + CPT and CPT alone in the improvement of BASDAI (*P* \> 0.05).

*(2) BASFI*. Two studies \[[@B44], [@B47]\] used the internationally recognized BASFI scoring standard. Yin et al. \[[@B44]\] thought that loading sinomenine hydrochloride sustained-release tablets based on sulfasalazine and meloxicam may reduce the BASFI more effectively (*P*=0.002). Jie et al. \[[@B47]\] thought that loading Zhengqing Fengtongning Injection based on CPT may reduce the BASFI more effectively (*P* \< 0.05).

*(3) Morning Stiffness Time (min)*. Seven studies \[[@B39], [@B41]--[@B46]\] using oral SP + CPT reported morning stiffness time. [Figure 4](#fig4){ref-type="fig"} shows a statistically significant difference, indicating that oral SP + CPT for treating AS may be more beneficial to shorten the morning stiffness time than CPT (WMD = −13.46, 95% CI \[−16.12, −10.79\], *P* \< 0.00001).

*(4) The Schober Test (cm)*. Five studies \[[@B39], [@B41]--[@B43], [@B45]\] using oral SP + CPT reported the Schober test. Because of the significant heterogeneity (*P*=0.06, *I*^2^ = 56%), a random-effect model was used. [Figure 5](#fig5){ref-type="fig"} shows that oral SP + CPT may be more beneficial to improve the Schober test than CPT in treating AS (WMD = 1.26, 95% CI \[0.72, 1.80\], *P* \< 0.00001). One study \[[@B47]\] using injectable SP + CPT reported the Schober test. Jie et al. \[[@B47]\] thought that there was no statistically significant difference between injectable SP + CPT and CPT alone in the improvement of the Schober test (*P* \> 0.05).

*(5) Chest Expansion (cm)*. Four studies \[[@B39], [@B42], [@B45], [@B46]\] using oral SP + CPT reported the chest expansion. [Figure 6](#fig6){ref-type="fig"} shows that it has not been proven that there is a statistically significant difference in the improvement of the chest expansion between oral SP + CPT and CPT (*P*=0.18). One study \[[@B47]\] using injectable SP + CPT reported the chest expansion. Jie et al. \[[@B47]\] thought that there was no statistically significant difference between injectable SP + CPT and CPT alone in the improvement of the chest expansion (*P* \> 0.05).

*(6) Occipital Wall Test (cm)*. Five studies \[[@B39]--[@B42], [@B45]\] using oral SP + CPT reported the occipital wall test. [Figure 7](#fig7){ref-type="fig"} shows that the difference is statistically significant, indicating that oral SP + CPT may be more beneficial to improve the symptoms of the occipital wall test than CPT in treating AS (WMD = −0.55, 95% CI \[−0.96, −0.14\], *P*=0.009).

*(7) Finger-to-Ground Distance (cm)*. Six studies \[[@B40]--[@B43], [@B45], [@B46]\] using oral SP + CPT reported finger-to-ground distances. [Figure 8](#fig8){ref-type="fig"} shows that the difference is statistically significant, indicating that oral SP + CPT may be more beneficial to improve the finger-to-ground distance than CPT in treating AS (WMD = −3.28, 95% CI \[−5.64, −0.93\], *P*=0.006).

*(8) 15* m *Walking Time (s)*. Two studies \[[@B42], [@B45]\] using oral SP + CPT reported 15 m walking time. [Figure 9](#fig9){ref-type="fig"} shows that the difference is statistically significant (WMD = −8.81, 95% CI \[−13.42, −4.20\], *P*=0.0002). Current evidence shows that oral SP + CPT for treating AS may be more beneficial to shorten the 15 m walking time than CPT.

### 3.4.2. Laboratory Measures {#sec3.4.2}

*(1) ESR (mm/h)*. Six studies \[[@B39], [@B41]--[@B43], [@B45], [@B46]\] using oral SP + CPT reported ESR. [Figure 10](#fig10){ref-type="fig"} shows that it has not been proven that there is a statistically significant difference in the improvement of ESR between oral SP + CPT and CPT (*P*=0.16). One study \[[@B47]\] using injectable SP + CPT reported ESR. Jie et al. \[[@B47]\] thought that there was no statistically significant difference between injectable SP + CPT and CPT alone in the improvement of ESR (*P* \> 0.05).

*(2) CRP (mg/l)*. Seven studies \[[@B39], [@B41]--[@B46]\] using oral SP + CPT reported CRP. [Figure 11](#fig11){ref-type="fig"} shows that oral SP + CPT may be more beneficial to improve CRP than CPT alone (WMD = −1.84, 95% CI \[−3.24, −0.45\], *P*=0.01). One study \[[@B47]\] using injectable SP + CPT reported CRP. Jie et al. \[[@B47]\] thought that there was no statistically significant difference between injectable SP + CPT and CPT alone in the improvement of CRP (*P* \> 0.05).

### 3.4.3. Total Effective Rate {#sec3.4.3}

Nine studies \[[@B39]--[@B47]\] all reported the total effective rate, four of which \[[@B39], [@B42], [@B45], [@B46]\] had consistent efficacy criteria. The effective criteria were at least 50% improvement in outcome measures such as ESR, CRP, morning stiffness time, number of joint swellings and pains, the Schober test, and chest expansion. Those who had achieved at least 3 criteria were effective as a whole; otherwise, they were ineffective. [Figure 12](#fig12){ref-type="fig"} shows that the difference is statistically significant, indicating that oral SP + CPT may be more beneficial to improve the total effective rate than CPT in treating AS (RR = 1.10, 95% CI \[1.01, 1.20\], *P*=0.03).

3.5. Data Analyses of SP Alone versus CPT {#sec3.5}
-----------------------------------------

The second type of intervention comparison was SP alone versus CPT, including two studies \[[@B49], [@B50]\]. The results of data analyses are as follows.

### 3.5.1. Clinical Symptom Measures {#sec3.5.1}

*(1) Morning Stiffness Time (min)*. Both studies \[[@B49], [@B50]\] reported the morning stiffness time. [Figure 13](#fig13){ref-type="fig"} shows that the difference is statistically significant (WMD = −31.89, 95% CI \[−34.91, −28.87\], *P* \< 0.00001). Current evidence shows that oral SP alone may be more beneficial in shortening the morning stiffness time of AS patients than sulfasalazine.

*(2) The Schober Test (cm)*. Both studies \[[@B49], [@B50]\] reported the Schober test. [Figure 14](#fig14){ref-type="fig"} shows that the difference is not statistically significant (WMD = 0.24, 95% CI \[−0.22, 0.70\], *P*=0.30). It has not been proven that there is a statistically significant difference in improving the symptoms of the Schober test between oral SP alone and sulfasalazine.

*(3) Chest Expansion (cm)*. Both studies \[[@B49], [@B50]\] reported chest expansion. [Figure 15](#fig15){ref-type="fig"} shows that the difference is not statistically significant (WMD = 0.06, 95% CI \[−0.11, 0.24\], *P*=0.48). It has not been proven that there is a statistically significant difference in improving chest expansion between oral SP alone and sulfasalazine.

*(4) Occipital Wall Test (cm)*. Both studies \[[@B49], [@B50]\] reported the occipital wall test. Because of the significant heterogeneity between the two studies (*P* \< 0.00001, *I*^2^ = 98%), a random-effect model was used. [Figure 16](#fig16){ref-type="fig"} shows that the difference is not statistically significant (WMD = −1.55, 95% CI \[−4.35, 1.25\], *P*=0.28). It has not been proven that there is a statistically significant difference in improving the occipital wall test between oral SP alone and sulfasalazine.

*(5) Finger-to-Ground Distance (cm)*. One study \[[@B49]\] reported finger-to-ground distance. The study \[[@B49]\] showed that there was no statistically significant difference between oral SP alone and sulfasalazine in improving the finger-to-ground distance (*P*=0.17).

### 3.5.2. Laboratory Measures {#sec3.5.2}

*(1) ESR (mm/h)*. Both studies \[[@B49], [@B50]\] using SP alone reported ESR. Because of the significant heterogeneity between the two studies (*P* \< 0.00001, *I*^2^ = 98%), a random-effect model was used. [Figure 17](#fig17){ref-type="fig"} shows that the difference is not statistically significant (WMD = −14.69, 95% CI \[−33.88, 4.50\], *P*=0.13). It has not been proven that there is a statistically significant difference in improving ESR between oral SP alone and sulfasalazine.

*(2) CRP (mg/l)*. Both studies \[[@B49], [@B50]\] using SP alone reported CRP. Since there was a methodological heterogeneity, SWD was selected as the effect amount. Because of the significant heterogeneity between the two studies (*P* \< 0.00001, *I*^2^ = 96%), a random-effect model was used. [Figure 18](#fig18){ref-type="fig"} shows that the difference is not statistically significant (SMD = −1.38, 95% CI \[−3.37, 0.61\], *P*=0.17). It has not been proven that there is a statistically significant difference in improving CRP between oral SP alone and sulfasalazine.

### 3.5.3. Total Effective Rate {#sec3.5.3}

Both studies \[[@B49], [@B50]\] were included and reported a total effective rate. No pooled analysis was performed due to inconsistent efficacy criteria. The results of the two studies showed that there was a significant difference (*P* \< 0.05), suggesting that oral SP alone might be more beneficial in the total effective rate of AS patients than sulfasalazine.

3.6. Adverse Reactions {#sec3.6}
----------------------

Ten studies \[[@B39]--[@B45], [@B47], [@B49], [@B50]\] reported adverse reactions. Two other studies \[[@B46], [@B48]\] did not report any information on adverse reactions. Adverse reactions included skin allergic reactions (rash or itching), digestive symptoms (gastrointestinal upset), systemic symptoms (headache or dizziness), abnormal laboratory indicators (liver and kidney dysfunction, elevated transaminases, decreased white blood cell count, or red blood cell urine), and drug allergy. Due to the wide variety of adverse reactions and the lack of consistent criteria for adverse reactions, no meta-analysis was performed. Therefore, we only conducted a descriptive analysis. In 7 studies \[[@B39]--[@B45]\] using oral SP + CPT versus CPT, 17 skin allergic reactions, 15 digestive symptoms, 0 systemic symptoms, 13 abnormal laboratory indicators, and 2 drug allergies (allergy to SP) occurred in the experimental group, and 8 skin allergic reactions, 7 digestive symptoms, 1 headache, 15 abnormal laboratory indicators, and 1 drug allergy (allergy to SSZ) occurred in the control group. In one study \[[@B47]\] using injectable SP + CPT versus CPT, 5 skin allergic reactions and 1 dizziness occurred in the experimental group, and no adverse reactions occurred in the control group. In 2 studies \[[@B49], [@B50]\] using oral SP alone versus CPT, 4 skin allergic reactions, 3 digestive symptoms, and 1 headache occurred in the experimental group, and 9 skin allergic reactions, 3 digestive symptoms, and 4 abnormal laboratory indicators occurred in the control group. In two studies \[[@B41], [@B44]\], patients withdrew from the study due to gastrointestinal reactions or allergic reactions. In other studies, adverse reactions were relieved or disappeared after discontinuation or symptomatic treatment. None of the 10 RCTs found statistically significant differences between the experimental group and the control group. See [Table 3](#tab3){ref-type="table"} for details.

4. Discussion {#sec4}
=============

4.1. Summary of Evidence for the Efficacy and Safety of Sinomenine {#sec4.1}
------------------------------------------------------------------

In this study, it has proven that oral SP + CPT may be more effective in treating AS compared with CPT alone in many indicators including BASDAI, morning stiffness time, Schober test, occipital wall test, finger-to-ground distance, 15 m walking time, CRP, and total effective rate, but it has not proven in BASFI, chest expansion, and SER. One study \[[@B47]\] showed that injectable SP + CPT may be more effective compared with CPT alone in BASFI, but no statistical significance in other indicators due to the insufficient number of studies included. It has also proven that oral SP alone may be more effective in improving morning stiffness time compared with CPT. Besides, there are no significant differences in adverse reactions between the experimental group and the control group, which indicates that SP may have good safety in the treatment of AS. Due to the insufficient number and low methodological quality of the included RCTs, it is impossible to carry out more multicenter, large-sample, and high-quality RCTs to further verify the conclusions.

Some scholars believed that the action of sinomenine on the mitogen-activated protein kinases (MAPKs) pathway could inhibit lipopolysaccharide-induced intercellular cell adhesion molecule-1 (ICAM-1) synthesis, which revealed the protective effect of sinomenine on postinflammatory vascular endothelium \[[@B27]\]. Besides, COX is an important rate-limiting enzyme in inflammation. It has two isoforms including COX-1 and COX-2. Generally, drugs exert their anti-inflammatory effects mainly by inhibiting COX-2. However, inhibition of COX-1 can cause adverse reactions. Traditional NSAIDs, such as ibuprofen and indomethacin, cannot selectively inhibit COX-1 and COX-2. The study \[[@B51]\] has found that sinomenine has a weak inhibitory effect on COX-1 enzyme activity within a certain concentration range and does not show a significant dose-effect relationship. Correspondingly, sinomenine has a stronger inhibitory effect on COX-2 enzyme activity. Therefore, sinomenine may selectively inhibit COX enzyme activity. And the chemical structure of sinomenine is similar to that of morphine, which has mild sedative and analgesic effects. Studies have confirmed that sinomenine can treat acute and chronic pain after inflammation and nerve injury, and there are no sedative and other side effects within the effective dose range \[[@B28]\]. This may be one of the reasons why sinomenine is effective in treating AS without obvious adverse reactions.

4.2. Limitations and Applicability of the Systematic Review and Meta-Analysis {#sec4.2}
-----------------------------------------------------------------------------

The high risk of bias in these RCTs was mainly due to inappropriate trial design and selective reporting. Serious inaccuracies are due to the small sample size of the included studies. The included studies were all published in Chinese and unpublished grey literature might not be retrieved, so the existence of publication bias could not be excluded. Therefore, the overall methodological quality of the included studies is low, which reduces the strength of evidence recommendation of this systematic review and meta-analysis. In the future, it is still necessary to carry out more multicenter, large-sample RCTs following the requirements of the SPIRIT 2013 statement (Defining Standard Protocol Items for Clinical Trials) \[[@B52]\] to further verify the conclusions. At the same time, we should pay more attention to the design and evaluation of clinical trials, improve the quality of evidence, use internationally accepted diagnostic criteria, and outcome measures that are closely related to efficacy \[[@B53]\].

Besides, the applicability of meta-analysis results was limited due to the reasons below. On the one hand, the follow-up time of the included RCTs was from one month to 18 months. Considering that the main purpose of our study is to observe whether SP is effective in patients with AS, therefore, the relationship between the follow-up time and the efficacy has not been explored in depth. In the future, more large samples and high-quality RCTs with the same follow-up time will be integrated to provide evidence of the time-effect relationship. On the other hand, in China, the commonly used symptom outcomes are morning stiffness time, the Schober test, chest expansion, occipital wall test, finger-to-ground distance, and 15 m walking time. However, these indicators are easily affected by the subjective consciousness of patients and evaluators. BASDAI and BASFI are internationally recognized symptom scales. As these scales are not widely used and promoted in China, only a few of the included RCTs use them. The unification and standardization of outcomes are important for effective and high-quality information mining based on a large number of clinical trials. Therefore, establishing the core outcome set of various diseases is the first problem that needs to be solved.

4.3. Prospects {#sec4.3}
--------------

Traditional Chinese medicine culture has been passed down in China for thousands of years. Chinese herbal medicine is an important part of traditional Chinese medicine culture. Chinese herbal medicine is not only rich in sources and low in price but also has great potential and research significance in the treatment of various diseases. By looking at the different cost areas within outpatient costs, Kirchhoff et al. found that medication costs played an important role, contributing approximately a third of the overall amount \[[@B54]\]. Currently, tumor necrosis factor inhibitor (TNFi) is a strongly recommended drug for the treatment of adults with active AS, even if an NSAID has been used \[[@B12]\]. However, the high cost of TNFi brings a heavy economic burden to families and society. SP is a Chinese herbal medicine extract, and its production cost is much lower than that of chemical drug synthesis. In the future, it is necessary to evaluate the cost-benefit of SP versus TNFi in the treatment of AS to provide more reliable evidence for further research and clinical decision making.

5. Conclusions {#sec5}
==============

In summary, this study shows that the combination of oral SP on the basis of CPT is more effective than CPT alone and its safety is good in the treatment of AS, which indicates that oral SP could be recommended as a potent and promising adjuvant therapy for AS. However, this study cannot provide evidence for the effect of injectable SP on AS due to few studies. In addition, due to the low methodological quality of the included RCTs and the limitations of the meta-analysis, it is still necessary to carry out more multicenter, large-sample, and high-quality RCTs to further verify the conclusions.
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Click here for additional data file.

![Flowchart of the literature selection process.](ECAM2020-4593412.001){#fig1}
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![Forest plot of BASDAI of oral SP + CPT versus CPT.](ECAM2020-4593412.003){#fig3}
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![Forest plot of the oral Schober test of oral SP + CPT versus CPT.](ECAM2020-4593412.005){#fig5}

![Forest plot of chest expansion of oral SP + CPT versus CPT.](ECAM2020-4593412.006){#fig6}

![Forest plot of occipital wall test of oral SP + CPT versus CPT.](ECAM2020-4593412.007){#fig7}

![Forest plot of the finger-to-ground distance of oral SP + CPT versus CPT.](ECAM2020-4593412.008){#fig8}

![Forest plot of 15 m walking time of oral SP + CPT versus CPT.](ECAM2020-4593412.009){#fig9}

![Forest plot of ESR of oral SP + CPT versus CPT.](ECAM2020-4593412.010){#fig10}

![Forest plot of CRP of oral SP + CPT versus CPT.](ECAM2020-4593412.011){#fig11}

![Forest plot of total effective rate of oral SP + CPT versus CPT.](ECAM2020-4593412.012){#fig12}

![Forest plot of morning stiffness time of SP alone versus CPT.](ECAM2020-4593412.013){#fig13}

![Forest plot of the Schober test of SP alone versus CPT.](ECAM2020-4593412.014){#fig14}

![Forest plot of chest expansion of SP alone versus CPT.](ECAM2020-4593412.015){#fig15}

![Forest plot of occipital wall test of SP alone versus CPT.](ECAM2020-4593412.016){#fig16}

![Forest plot of ESR of SP alone versus CPT.](ECAM2020-4593412.017){#fig17}

![Forest plot of CRP of SP alone versus CPT.](ECAM2020-4593412.018){#fig18}

###### 

Search strategy in PubMed.

  Search   Query                                                                                                         Items found
  -------- ------------------------------------------------------------------------------------------------------------- -------------
  \#1      Sinomenine\[Title/Abstract\]                                                                                  403
  \#2      Sinomenium\[Title/Abstract\]                                                                                  151
  \#3      Zhengqing Fengtongning\[Title/Abstract\]                                                                      9
  \#4      Zhengqingfengtongning\[Title/Abstract\]                                                                       0
  \#5      \#1 OR \#2 OR \#3 OR \#4                                                                                      449
  \#6      Spondylitis, Ankylosing\[MeSH Terms\]                                                                         14294
  \#7      Ankylosing spondylitis\[Title/Abstract\]                                                                      13433
  \#8      \#6 OR \#7                                                                                                    18400
  \#9      Randomized controlled Trials as Topic\[MeSH Terms\]                                                           130251
  \#10     Randomized controlled Trial\[Publication Type\]                                                               492614
  \#11     Controlled clinical Trial\[Publication Type\]                                                                 581079
  \#12     Equivalence Trial\[Publication Type\]                                                                         392
  \#13     Randomized controlled trial\[Title/Abstract\]                                                                 65358
  \#14     Random Allocation\[MeSH Terms\]                                                                               100812
  \#15     Double-Blind Method\[MeSH Terms\]                                                                             153964
  \#16     Single-Blind Method\[MeSH Terms\]                                                                             27468
  \#17     Clinical Trial\[Publication Type\]                                                                            839529
  \#18     Research Design\[MeSH Terms\]                                                                                 428214
  \#19     Placebos\[MeSH Terms\]                                                                                        34533
  \#20     placebo\$\[Title/Abstract\]                                                                                   207201
  \#21     random*∗*\[Title/Abstract\]                                                                                   1081385
  \#22     trial\$\[Title\]                                                                                              206169
  \#23     \#9 OR \#10 OR \#11 OR \#12 OR \#13 OR \#14 OR \#15 OR \#16 OR \#17 OR \#18 OR \#19 OR \#20 OR \#21 OR \#22   1854129
  \#24     \#5 AND \#8 AND \#23                                                                                          1

###### 

Characteristics of the studies included.

  Study ID           Sample size (E/C)   Sex (M/F)   Age (mean ± SD or range)   Duration of disease (Mean ± SD or range)   Intervention   Follow-up time    Outcomes                                                                                                                               
  ------------------ ------------------- ----------- -------------------------- ------------------------------------------ -------------- ----------------- ----------------- ----------------------------------------------------------------- ------------------------------------- ------------ ------------
  Liu \[[@B39]\]     36/32               29/7        24/8                       24.0 ± 4.8                                 22.0 ± 5.4     (4.8 ± 3.6) y     (4.5 ± 3.2) y     SP (ZFCT\[po, 40 mg, tid\]) + CPT                                 CPT (SSZ)                             18 m         ①②③④⑤⑥⑦⑧
  Liu \[[@B40]\]     30/20               26/4        18/2                       15∼39                                      17∼58          (0.5∼5) y         (0.5∼6) y         SP (ZFCT\[po, 80 mg, tid\]) + CPT                                 CPT (SSZ)                             3 m          ④⑦⑧⑨
  Dong \[[@B41]\]    45/34               42/3        32/2                       24∼72                                      26∼72          NA                NA                SP (ZFCT\[po, 40 mg, tid\]) + CPT                                 CPT (SSZ + Meloxicam)                 24 w (6 m)   ①②④⑤⑥⑧⑨
  Yang \[[@B42]\]    38/38               31/7        33/5                       30.26 ± 13.4                               28.67 ± 12.8   (5.31 ± 2.8) y    (6.04 ± 3.1) y    SP (ZFSRT\[po, 60 mg, bid\]) + CPT                                CPT (SSZ)                             12 w (3 m)   ①②③④⑤⑥⑦⑧⑨⑩
  Huang \[[@B43]\]   13/12               NA          NA                         NA                                         NA             NA                NA                SP (ZFSRT\[po, 60 mg, bid\]) + CPT                                CPT (SSZ)                             6 m          ①②⑤⑦⑧⑨
  Yin \[[@B44]\]     31/30               28/6        25/9                       26.4 ± 3.5                                 29.8 ± 2.2     (5.9 ± 1.8) y     (6.1 ± 4.2) y     SP (ZFSRT\[po, 60 mg, bid\]) + CPT                                CPT (SSZ)                             12 m         ①⑥⑧⑪⑫
  Lin \[[@B45]\]     57/58               NA          NA                         23.5 ± 13.4                                24.7 ± 11.3    3 m∼11 y          5 m∼12 y          SP (ZFSRT\[po, 120 mg, bid\]) + CPT                               CPT (SSZ + NSAIDs + methotrexate)     12 m         ①②③④⑤⑥⑦⑧⑨⑩
  Yu \[[@B46]\]      40/40               32/8        30/10                      27.2 ± 3.0                                 26.7 ± 3.3     (6.1 ± 1.2) y     (5.7 ± 1.5) y     SP (ZFSRT\[po, 120 mg, bid\]) +CPT                                CPT (SSZ + Thalidomide + Meloxicam)   3 m          ①③④⑤⑥⑦⑨⑪
  Jie \[[@B47]\]     32/30               NR          NR                         NR                                         .NR            NR                NR                SP (ZFI\[intra-articular injection, 35 ml, once a week\]) + CPT   CPT (SSZ/Meloxicam)                   1 m          ②③⑤⑥⑦⑧⑪⑫
  An \[[@B48]\]      25/24               19/6        20/4                       30.2 ± 8.0                                 31.3 ± 7.0     (6.3 ± 1) y       (6.9 ± 0.8) y     SP (ZFI\[intra-articular injection, 2 ml, qod\]) + CPT            CPT (IPT + vitamins + Ranitidine)     1 m          ⑦
  Liu \[[@B49]\]     60/60               NA          NA                         26.5 ± 4.8                                 26 ± 4.5       6 m∼14 y          6 m∼13 y          SP (ZFSRT\[po, 60 mg, bid\])                                      CPT (SSZ)                             3 m          ①②③④⑤⑥⑦⑧⑨
  Chai \[[@B50]\]    28/22               22/6        29/7                       28.63 ± 5.23                               27.98 ± 3.85   (4.87 ± 1.09) y   (4.91 ± 1.27) y   SP (ZFSRT\[po, 120 mg, bid\])                                     CPT (SSZ)                             2 m          ①②③④⑤⑥⑦⑧

*Note.* E: experimental group; C: control group; M: male; F: female; ZFCT: Zhengqing Fengtongning Conventional Tablet; ZFSRT: Zhengqing Fengtongning Sustained Release Tablet; ZFI: Zhengqing Fengtongning Injection; SSZ: sulfasalazine; NSAIDs: nonsteroidal anti-inflammatory drugs; IPT: inflammatory pain tablet; po: oral preparation; tid: three times a day; bid: twice a day; qod: every other day; y: year; m: month; w: week; NA: not available; ① morning stiffness time; ② Schober test; ③ chest expansion; ④ occipital wall test; ⑤ erythrocyte sedimentation rate (ESR); ⑥ C-reactive protein (CRP); ⑦ total effective rate; ⑧ adverse reactions; ⑨ finger-to-ground distance; ⑩ 15 m walking time; ⑪ Bath ankylosing spondylitis disease activity index (BASDAI); ⑫ Bath ankylosing spondylitis functional index (BASFI).

###### 

Summary of adverse reactions.

  Study ID           Experimental group   Control group                                                                                                                                                                                                          
  ------------------ -------------------- ----------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- ---- ----------------------------- -----------------------------------------------------------------------------------------------------------------
  Liu \[[@B39]\]     36                   SP (ZFCT\[po, 40 mg, tid\]) + CPT                                 Rash or pruritus: 2; gastrointestinal upset: 3; decreased WBC: 1                                                  32   SSZ                           Rash or pruritus: 1; gastrointestinal upset: 3; headache: 1
  Liu \[[@B40]\]     30                   SP (ZFCT\[po, 80 mg, tid\]) + CPT                                 0                                                                                                                 20   SSZ                           0
  Dong \[[@B41]\]    45                   SP (ZFCT\[po, 40 mg, tid\]) + CPT                                 Gastrointestinal upset: 2; drug allergy (SP): 2                                                                   34   SSZ + Meloxicam               Gastrointestinal upset: 2; drug allergy (SSZ): 1
  Yang \[[@B42]\]    38                   SP (ZFSRT\[po, 60 mg, bid\]) + CPT                                Rash or pruritus: 4                                                                                               38   SSZ                           0
  Huang \[[@B43]\]   13                   SP (ZFSRT\[po, 60 mg, bid\]) + CPT                                Rash or pruritus: 1                                                                                               12   SSZ                           Liver and kidney dysfunction: 2
  Yin \[[@B44]\]     31                   SP (ZFSRT\[po, 60 mg, bid\]) + CPT                                Rash or pruritus: 5; gastrointestinal upset: 3; decreased WBC: 2; liver and kidney dysfunction: 1; RBC urine: 4   30   SSZ                           Rash or pruritus: 1; gastrointestinal upset: 2; decreased WBC: 2; liver and kidney dysfunction: 2; RBC urine: 3
  Lin \[[@B45]\]     57                   SP (ZFSRT\[po, 120 mg, bid\]) + CPT                               Rash or pruritus: 5; gastrointestinal upset: 7; elevated transaminase: 5                                          58   SSZ + NSAIDs + methotrexate   Rash or pruritus: 6; elevated transaminase: 6
  Jie \[[@B47]\]     32                   SP (ZFI\[intra-articular injection, 35 ml, once a week\]) + CPT   Rash or pruritus: 5; dizziness: 1                                                                                 30   SSZ/Meloxicam                 0
  Liu \[[@B49]\]     60                   SP (ZFSRT\[po, 60 mg, bid\])                                      Rash or pruritus: 3                                                                                               60   SSZ                           Rash or pruritus: 7; elevated transaminase: 3
  Chai \[[@B50]\]    28                   SP (ZFSRT\[po, 120 mg, bid\])                                     Rash or pruritus: 1; gastrointestinal upset: 3; headache: 1                                                       22   SSZ                           Rash or pruritus: 2; gastrointestinal upset: 3; decreased WBC: 1

*Note.* ZFCT: Zhengqing Fengtongning Conventional Tablet; ZFSRT: Zhengqing Fengtongning Sustained Release Tablet; ZFI: Zhengqing Fengtongning Injection; SSZ: sulfasalazine; NSAIDs: nonsteroidal anti-inflammatory drugs; IPT: inflammatory pain tablet; po: oral preparation; tid: three times a day; bid: twice a day; WBC: white blood cell; RBC: red blood cell.

[^1]: Guest Editor: Yuan Xu
